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Biological systems are exquisitely sensitive to the location and
timing of physiologic cues and drugs. This spatiotemporal sensitivity
presents opportunities for developing new therapeutic approaches.
Polymer-based delivery systems are used extensively for attaining
localized, sustained release of bioactive molecules. However, these
devices typically are designed to achieve a constant rate of release.
We hypothesized that it would be possible to create digital drug
release, which could be accelerated and then switched back off, on
demand, by applying ultrasound to disrupt ionically cross-linked
hydrogels. We demonstrated that ultrasound does not perma-
nently damage these materials but enables nearly digital release
of small molecules, proteins, and condensed oligonucleotides. Par-
allel in vitro studies demonstrated that the concept of applying
temporally short, high-dose “bursts” of drug exposure could be
a p p l i e dt oe n h a n c et h et o x i c i t yo f mitoxantrone toward breast
cancer cells. We thus used the hydrogel system in vivo to treat
xenograft tumors with mitoxantrone, and found that daily ultra-
sound-stimulated drug release substantially reduced tumor growth
compared with sustained drug release alone. This approach of dig-
ital drug release likely will be applicable to a broad variety of poly-
mers and bioactive molecules, and is a potentially useful tool for
studying how the timing of factor delivery controls cell fate in vivo.
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P
olymer-based systems for drug delivery typically are engi-
neered to yield a constant rate of release of bioactive com-
pounds (1). Emergent clinical situations (e.g., pain attacks or
infections) may create a need for significantly different drug
doses over short periods, and in some cases, circadian drug
timing increases effectiveness (2, 3). Likewise, controlled-release
systems may be applied to dissect roles for specific physiologic
cues or drugs during tissue development or regeneration, as
these signals often are highly transient and may play opposite
roles, depending on the timing of activation (4–7). Typical drug
delivery systems that rely on polymer degradation and passive
diffusion to control release allow precise spatial localization of
cues, but not the ability to temporally control release rates at
will. In contrast, on-demand release systems, such as “smart”
polymers or materials activated by external stimuli [e.g., mag-
netic fields, radio waves, or light (8–13)] potentially offer this
temporal flexibility and are beginning to be applied in the clinical
setting (14). Ultrasound commonly is used in medicine and can
deliver focused energy of varying magnitude and frequency with
high spatiotemporal resolution (15). In particular, ultrasound has
been used to trigger release from polymers by causing their
degradation (16, 17). This degradation permanently changes the
delivery vehicle, thus altering the baseline rate of molecular re-
lease as well as the release achieved with subsequent exposure to
ultrasound. Interestingly, ultrasound also is used in a process
known as sonophoresis, in which sound waves are applied to
disrupt skin transiently for needle-free transdermal drug delivery
(15, 18). A crucial difference between sonophoresis and ultra-
sound-stimulated polymer degradation is that the damage in-
duced by cavitation during sonophoresis is only temporary,
because skin has a self-healing capability that switches delivery
off following removal of the ultrasound stimulus. Because self-
healing causes skin to revert to its basal state following removal
of the ultrasound stimulus, repeated sonophoresis yields similar
doses during each pulse (15, 18). A hydrophobic coating on
a drug-containing polymer disk was shown to be disrupted by
ultrasound and subsequently to reform on the polymer returning
release to baseline; however, a self-healing coating is susceptible
to replacement by nonspecific adhesion of proteins and cells in
vivo, which would result in unpredictable release kinetics (19).
Thus, we sought to develop an injectable monolithic system that
can hold more drug per unit volume, responds to ultrasound, and
subsequently self-heals. We first demonstrated that monolithic
alginate hydrogels exhibited such behavior, and that this enabled
on-demand delivery of drugs, cytokines, and condensed plasmid
DNA (pDNA). In vitro experiments demonstrated that human
breast cancer cells were more sensitive to high-dose “pulses” of
the chemotherapeutic drug mitoxantrone than they were to the
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period, which motivated us to apply the drug-loaded monolithic
alginate system to treat breast cancer xenografts. Treatment of
xenograft breast tumors with a drug-laden gel was more effective
when a daily pulse of ultrasound was applied. These findings
indicate that the timing, as well as the localization of drug de-
livery, both influence efficacy toward chemotherapy and suggest
classes of hydrogel systems that might be used to identify optimal
treatment regimens and ultimately apply them clinically.
Results and Discussion
To test whether there were injectable and monolithic biomaterials
that could exhibit self-healing characteristics that would allow
repeated and reversible ultrasound-induced disruption (and con-
current drug release) in a manner analogous to skin sonophoresis,
we first examined alginate (20), a polysaccharide that forms a
hydrogel via ionic cross-linking with divalent cations (e.g., Ca
2+).
We hypothesized that ultrasound could disrupt calcium cross-
links to accelerate drug release, but the presence of Ca
2+ in phys-
iological fluids would allow cross-links to reform upon removal
of the stimulus (Fig. 1A), facilitating reversible, on-demand
release. On both the macroscopic and microscopic levels, sub-
stantial disruption of the structure of ionically cross-linked hydro-
gels was apparent after ultrasound treatment in the absence of
physiologic levels of free divalent cations (Fig. 1 B and C). In-
terestingly, the levels of applied ultrasound power required to
achieve these effects were similar to levels previously used in
sonophoresis (18). In contrast, subjecting hydrogels to ultrasound
treatment in the presence of free divalent cations resulted in no
observable, permanent disruption of the gel structure after ces-
sation of ultrasound, as treated gels looked identical to untreated
controls (Fig. 1D). Mechanical properties analysis was consistent
with these structural observations: the dry mass of calcium alginate
hydrogels after treatment remained unchanged as long as gels
were incubated in media with physiologic Ca
2+ levels (2.6 mM;
Fig. 1E), whereas it dropped substantially when gels were treated
with ultrasound while maintained in Ca
2+-depleted saline. This
finding was verified further by measurements of elastic modulus,
a more sensitive metric of relative cross-link density and me-
chanical integrity than dry mass (Fig. 1F). Consistent with the
hypothesis that cross-links reform upon removal of the ultra-
sound in a manner dependent on the presence of free calcium
in the surrounding fluid, calcium alginate gels bathed in media
with supraphysiological Ca
2+ levels became stiffer upon repeated
ultrasound treatment (Fig. 1F).
The possibility of using reversible, ultrasound-triggered dis-
ruption of ionic cross-links to induce bursts of drug release was
investigated next. Mitoxantrone, an anthracycline commonly used
to treat breast cancer, is a charged molecule that forms an ionic
complex with alginate (21) and thus exhibited a low baseline
level of release from alginate gels in the absence of ultrasound
(Fig. 2 A and C). One of the drawbacks of mitoxantrone clinically
is its off-target toxicity, which may be minimized in this system by
local delivery of the chemotherapeutic. To monitor ultrasound-
induced release, drug-loaded, preswollen hydrogels were moved
to fresh media and pulsed with ultrasound. Immediately fol-
lowing treatment, gels were moved to a new container to monitor
release without stimulus. To account for any release induced by
mechanical handling (22), gels not exposed to ultrasound also
were moved to new media at the same time intervals. Handling
alone had a minor, albeit detectable, effect on the release rate of
mitoxantrone in the absence of ultrasound (Fig. 2 A and C).
Pulsatile ultrasound application triggered mitoxantrone release,
leading to visible depletion of the drug (blue) from hydrogels and
accumulation within the media surrounding the gels (Fig. 2 B
and C). To test ultrasound-mediated release in vivo, we switched
to a shear-thinning gel formulation that could be delivered pre-
cisely and noninvasively (23). This gel formulation exhibited sim-
ilar, ultrasound-triggered drug release, again without undergoing
degradation (as judged by the reversibility of release kinetics when
ultrasound was removed) in vitro (Fig. S1), compared with the
original formulation. In vivo, even a single pulse of ultrasound
substantially increased drug release into the s.c. space in nude
mice (Fig. 2 D and E).
The broader utility of ultrasound-stimulated gel disruption
toward macromolecular delivery next was tested on condensed
oligonucleotides and cytokines. Positively charged condensed
pDNA and the extracellular matrix-binding cytokine stromal cell-
derived factor 1α (SDF-1α) both interact strongly with alginate
(13, 24), minimizing their baseline levels of release from non-
degrading hydrogels. Like mitoxantrone, both these macromole-
cules were released in a pulsatile manner via ultrasound treatment
(Fig. 2 F and G), leading to stepwise accumulation in the me-
dium surrounding the gels. VEGF-165, another cytokine that
interacts noncovalently with alginate (22), although not with the
same strength as SDF-1α, also was released in an on-demand
manner with ultrasound (Fig. S2). Further mechanistic studies
were consistent with the assumption that ultrasound causes on-
demand drug release via transient gel disruption and that the pri-
mary means of release is through the gel surface (SI Materials and
Methods and Figs. S3–S5).
To determine whether reversible, ultrasound-triggered release
is possible with other types of hydrogels, we investigated the
release of naproxen (a negatively charged nonsteroidal anti-
inflammatory drug) from ionic hydrogels formed by cross-linking
the polycationic polymer chitosan with tripolyphosphate (TPP).
Fig. 1. Ultrasound-induced disruption and self-healing of ionically cross-
linked hydrogels. (A) Schematic of the proposed ability of ultrasound to
induce transient disruption of hydrogels cross-linked by calcium, followed by
reformation of cross-links by calcium within physiologic fluids, resulting in
gel healing. Calcium (●) binds selectively to guluronic acid chains (yellow) of
alginate polymers. (B–D). Scanning electron micrographs (SEMs) of the mi-
crostructure (Left) and photographs of the gross structure (Right)o f( B)
calcium alginate hydrogels before ultrasound, (C) calcium alginate hydrogels
after treatment with ultrasound in medium without divalent cations, and (D)
calcium alginate hydrogels after treatment with ultrasound in medium with
physiologic levels of Ca
2+.( E and F) Normalized dry mass (E) and normalized
elastic modulus (F) of alginate hydrogels exposed to ultrasound while
bathing in medium without divalent cations (○), media with 2.6 mM Ca
2+
(blue ◆), or media with a supraphysiologic concentration (13.3 mM) of Ca
2+
(red ▲). Error bars: SD, n = 4. Scale bars (B–D): SEM, 200 μm; photographs, 5 mm.
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SUltrasound treatment significantly enhanced naproxen release
from these materials (Fig. 2H). Accordingly, these data suggest
that a wide variety of bioactive molecules might be released in
a pulsatile fashion, given the appropriately selected drug–gel
pairing. With the appropriate choice of drugs and/or carrier mole-
cules, one may be able to integrate ultrasound-mediated drug
delivery into complex devices that release multiple compounds
over different time frames (14).
As cancer cells specifically have been shown to exhibit dy-
namic responses to drug treatment (3, 4), we hypothesized that
intermittent, higher pulses of drug dose might enhance the effects
of chemotherapeutic drugs such as mitoxantrone. To test this
hypothesis, we first analyzed the effects of controlling the timing
of dose profiles on mitoxantrone-treated cancer cells in vitro.
Two human breast cancer lines (MDA-MB-231 and MCF7) were
treated with two different dose profiles of drug: (i) an interme-
diate, constant dose or (ii) a combination of short duration, high
concentration of drug with sustained exposure to a lower base-
line dose. Drug concentrations were altered via media exchange
to prevent confounding of the study results by exposing cells to
ultrasound or to drugs released from gels via ultrasound, and
with every media change, all samples were washed thoroughly
with PBS and fresh media was added to avoid any confounding
effects of residual drug (from previous dosings) or media ex-
change on cell viability. The integrated value of drug dose over
time (e.g., total drug exposure) to which cells were exposed was
maintained constant. Interestingly, the combination of tempo-
rally short exposure to a burst of drug with a low baseline dose
appeared to be much more effective than sustained exposure to
mitoxantrone in reducing cancer cell viability (Fig. 3 A–C). Ad-
ditional studies indicated that the total drug exposure also sig-
nificantly contributes to the effects of mitoxantrone (Fig. S6).
These results are consistent with previous work indicating that
the dynamics of drug exposure have substantial effects on cell-
level responses (4, 5), highlighting the importance of studying
cell response to drug dynamics and the necessity for robust sys-
tems that facilitate these delivery modes in vitro and in vivo.
We then analyzed how the dynamics of mitoxantrone exposure
affected viability in these cells. MDA-MB-231 cells were used
in these studies, as they represent a more metastatic popula-
tion than MCF7 breast cancer cells. The enhanced ability of
a pulse of mitoxantrone to diminish cell viability was consistent
across several dosing profiles (Fig. 3D). Further, increasing the
time of burst exposure while diminishing the concentration
during burst (to maintain the same level of integrated drug ex-
posure) diminished the effect of mitoxantrone, whereas using an
even shorter burst time with a higher dose enhanced its effects
(Fig. 3D).
Having established the potential therapeutic utility of combin-
ing short bursts of concentrated drug release with a baseline, lower
dose of drug in vitro and identifying a set of biomaterials that
would allow such profiles to be delivered in vivo, we investigated
the effects of ultrasound-mediated mitoxantrone delivery on
treatment of xenograft human breast tumors (MDA-MB-231) in
nude mice. First, short-term studies were performed to identify
effects of ultrasound-mediated drug delivery on tumor growth and
apoptosis. TUNEL staining of tumors after 8 d of treatment
revealed that implanting mitoxantrone-laden alginate matrices
led to significant apoptosis in the xenografts, regardless of whether
a daily dose of ultrasound was applied to induce burst release
(Fig. 4 A and B). In contrast, systemic drug delivery of the
equivalent amount of drug delivered via bolus tail vein injection
did not lead to substantial apoptosis. This finding is consistent
with literature reports of the poor ability of systemically de-
livered mitoxantrone to reach xenograft tumors [<5% of sys-
temic dose typically found at xenograft hindlimb tumor site (25)].
Interestingly, daily local drug injections, or a bolus drug injection
combined with daily ultrasound, yielded little to no improvement
in xenograft apoptosis over tail vein injection. Although these
results do not rule out the possibility that ultrasound might en-
hance tissue permeability, thereby increasing drug potency, they
strongly suggest that a locally deployed drug depot is required to
maintain a baseline concentration of bioactive drug. Consistent
with this assumption, measurements of relative tumor size re-
vealed that both a daily local injection of drug and the combi-
nation of basal delivery from a hydrogel combined with a daily
ultrasound pulse led to a reduction in tumor size, but only the
combined regimen yielded tumors that were statistically differ-
ent in size than tumors from mice subjected to a systemic (tail
vein) dose (Fig. 4C). Combined with the finding that drug-laden
gels, with or without ultrasound pulsing, yielded significant levels
of xenograft apoptosis, this suggests that the levels of mitoxan-
trone to which tumors are exposed are sufficient for eliminating
tumors, but that a basal level of apoptosis is reached earlier in
tumors in which drug-laden gels are pulsed with ultrasound, which
translates into a substantial reduction in tumor mass. Thus, these
data suggest that combining a local, basal release with intermittent
Fig. 2. Ultrasound-mediated on-demand release from ionically cross-linked
hydrogels. (A and B) Quantitative analysis of mitoxantrone release via dif-
fusion (A) or ultrasound treatment (B; 5 min, applied once every hour). Data
indicate ultrasound intensity (Left), mitoxantrone release rate (Center), and
cumulative mitoxantrone release (Right). (C) Representative images of re-
sidual mitoxantrone (blue) contained in alginate hydrogels after they were
treated with ultrasound once per hour over 10 h (Right) or not treated with
ultrasound (Left). (D) Representative images of residual mitoxantrone con-
tained in alginate hydrogels, and mitoxantrone released from gels and
subsequently deposited into host tissues, after hydrogels were transplanted
into Nu/J mice and treated once with ultrasound for 2.5 min (Right)o rl e f t
untreated (Left) over a 24-h period. (E) Quantitative analysis of the extent of
in vivo mitoxantrone release, determined by the total surface area of s.c.
tissue displaying visible staining with the drug (blue) normalized to the area
of the transplanted gels. (F) Cumulative delivery of SDF-1α from hydrogels
that were treated with ultrasound for 10 min once every 2 h. (G) Cumulative
delivery of pDNA condensed with poly(ethylene imine) from hydrogels that
were treated with ultrasound for 10 min once every day. (H) Cumulative
delivery of naproxen from TPP–chitosan hydrogels treated with ultrasound
for 10 minutes once every 2 h. Error bars: SD, n = 3–4. *P < 0.05, t test.
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course of therapy.
Based on the results of our short-term studies, subsequent
long-term studies on tumor growth and host survival were per-
formed using locally deployed alginate gels. Tumors within mice
receiving no therapy grew rapidly, and these animals succumbed
to the effects of tumors within 100 d. Treatment with mitoxan-
trone-eluting gels alone decreased tumor growth rate and im-
proved survival, as expected, with the time to 50% animal mortality
increasing from 100 to 120 d (Fig. 4 D and E). Strikingly, the
combination of low-level sustained release with a daily concen-
trated pulse of mitoxantrone delivered via ultrasound reduced
the growth rate of xenograft tumors compared with treatment
with mitoxantrone-laden gels alone (Fig. 4D). Importantly, this
treatment improved survival of mice bearing these tumors after
all treatments had stopped, with the time to 50% animal mor-
tality nearly doubling from the value of 100 d for mice receiving
no therapy to 180 d (Fig. 4E). Kaplan–Meir analysis revealed
a statistically significant survival improvement in mice treated
with either drug-laden gels or drug-laden gels exposed to a daily
pulse of ultrasound, compared with mice receiving no therapy.
Although survival did not improve significantly when daily ultra-
sound pulses were applied on top of the drug-laden gels, tumors
were significantly smaller in this treatment group (compared with
tumors in mice receiving only drug-laden gels) from days 10
through 70 of treatment (with the exception of days 24–31 and
days 59–63). Notably, the drug payload within ultrasound-treated
gels is depleted faster than the drug within gels loaded with drug
but not exposed to this stimulus (Fig. S7)—hence, mitoxantrone-
laden gels not treated with ultrasound continued to release drug
for a longer period; thus, the net amount of drug delivered to
tumors over the course of this study was the same between these
conditions. These results suggest that although localized mitox-
antrone delivery is therapeutic, its effectiveness—and likely the
effectiveness of other existing drugs—may be improved with
optimal spatial as well as temporal delivery.
At the end of the 6-mo study period, surviving mice were
euthanized and the masses of remaining tumors were analyzed.
Tumors within surviving mice that had received a combination
of ultrasound and mitoxantrone-laden hydrogels had not grown
substantially since the start of treatment (Fig. 4F) and had a net
mass of 63 ± 45 mg. In contrast, among tumors retrieved from
surviving mice that had received mitoxantrone-laden hydrogels
but not ultrasound, only one of the remaining tumors weighed
less than 100 mg, whereas the other weighed nearly 1 g, or the
approximate mass of tumors explanted from drug-treated mice
that succumbed to tumors earlier in the study (1,100 ± 800 mg).
Although the current studies demonstrate the potential of
ultrasound-stimulated drug release to enhance chemotherapy, it
is noted that further testing mimicking the exact application is
required before its clinical adoption. The ultrasound intensities
are within those used by other authors for ultrasound-stimulated
drug release and were demonstrated to be safe in animal testing
(17, 18). More sophisticated ultrasound devices that focus the
signal on the gel would allow deeper implantation of the gel and
mitigate any potential side effects. Such devices also would allow
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Fig. 3. Dynamics of mitoxantrone exposure affects drug effects on viability of human breast cancer cells in vitro. (A) Schematics depicting constant drug
concentration, representative of the dose that would be expected with standard drug-delivering biomaterials (Left), or a lower baseline dose, interspersed
with a high dose presented in a pulsatile fashion (Right), representative of the dose expected with on-demand release. Note that the integrated dose is the
same. (B) Representative fluorescence micrographs of mCherry-labeled MDA-MB-231 breast cancer cells exposed to a sustained mitoxantrone dose (Center)o r
a lower baseline drug dose interspersed with a periodic high dose, applied for 10 min once every 12 h (Left). (C) Quantitative analysis of cell viability in MDA-
MB-231 (blue) and MCF7 (red) breast cancer cell lines treated with sustained or pulsatile exposure to mitoxantrone. The cycle was performed once every1 2h
and repeated five times, and the total drug exposure was constant at 12 μg·mL
−1·h
−1 in both conditions. (D) Quantitative analysis of MDA-MB-231 viability
after 60 h of various mitoxantrone dosing regimens. (E) Table detailing the dosing regimens used for D. Error bars: SD, n = 4( * * P < 0.05, two-tailed t-test),
n = 3–9. Scale bars (B): 200 μm.
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Sxenograft tumors to be implanted directly into the mammary
gland (i.e., orthotopic models) or would enable the use of mouse
models in which breast tumors develop spontaneously (26, 27).
In the present study, the mammary gland was avoided because
the distance between the skin and lungs in the mouse is very short
compared with the distance between these tissues in humans.
Alginate gels previously were used clinically and have been
tested by numerous investigators in animal models, supporting
the eventual application of this material in clinical use. As dem-
onstrated here, other types of hydrogels (or appropriate carrier
molecules) may be necessary for pulsatile delivery of molecules
with substantially different charge or structure compared with
mitoxantrone (e.g., naproxen). Applications that may benefit from
intermittent high pulsing (e.g., cancer therapy, pain management)
or from applications that require release of a drug or factor at
specific time points (e.g., in tissue engineering) might benefit
greatly from the described system.
Together, the results presented here indicate that self-healing,
ionically cross-linked polymers subject to ultrasonic irradiation
can trigger on-demand drug delivery in vivo and augment the
effects of sustained, baseline release. We also demonstrate a
potential therapeutic application of this technology. Combining
mitoxantrone with other drugs or macromolecules [e.g., siRNAs
(28)] likely will further enhance the therapeutic efficacy of this
system. We expect this technology to be applied to many poly-
mers that form ionically or physically cross-linked gels, enabling
externally triggered release of a wide variety of factors, including
small molecules, proteins, nucleic acids, and nanoparticles (29–
31). Beyond clinical applications, this technique also may be useful
in fundamental studies of how the delivery profile or timing of
application of bioactive agents modulates tissue development,
pathology, and regeneration.
Materials and Methods
Alginate Hydrogels and Analysis of Self-Healing. Medical grade, high guluronic
acid-content, high Mr alginate (MVG) was purchased from FMC Biopolymers.
Alginates were dialyzed against water, filtered (0.22-μm mesh), freeze dried,
and resuspended into Dulbecco’s PBS (dPBS; Invitrogen). For drug, protein,
and pDNA release studies, the alginate polymers first were combined with
the molecule of interest to facilitate noncovalent interactions. Next, alginate
was cross-linked with calcium sulfate (CaSO4; Sigma) to a final concentration
of 50 mM Ca
2+ and 20 mg/mL MVG within gels, and a biopsy punch was used
to obtain gels of a defined size and shape. Hydrogels were equilibrated
overnight in serum free DMEM without phenol red (Invitrogen). Next, gels
were transferred to 15-mL tubes filled with dPBS with an additional 0–13.3
mM Ca
2+. Gels were subjected to ultrasound treatment (9.6 mW/cm
2, 5-min
pulses, once per hour). The power and time of ultrasound application were
chosen based upon measurements of the temperature of media subjected to
ultrasound, and within the range used here, temperature change did not
exceed controls (controls were kept at 37 °C; ultrasound was done at room
temperature, and the media temperature remained <32 °C), allowing any
change in molecular diffusion coefficients or hydrogel degradation via heat
to be ruled out of our analysis. To assess gross structural changes, gels that
had been subjected to four ultrasound treatments were photographed and
immediately flash frozen in liquid nitrogen. After freeze drying, ultrastruc-
ture was assessed using a Zeiss EVO scanning electron microscope at the
Harvard Center for Nanoscale Systems. To detect cross-linking changes, gels
were subjected to a set number of ultrasound treatments, and elastic modulus
was measured using an Intron 3342 mechanical testing apparatus. Immedi-
ately after modulus testing, gels were flash frozen and lyophilized to obtain
their dry masses.
In Vitro Hydrogel Self-Healing and Release Studies. Drug-, protein-, or pDNA-
laden alginate gels were cast. The final concentration of each bioactive agent
within gels was as follows: mitoxantrone, 850 μg/mL of gel; SDF-1α (Pepro-
tech), 20 μg/mL of gel; pDNA (gWiz GFP plasmid DNA, Aldevron), 100 μg/mL
of gel. Ultrasound was applied at 9.6 mW/cm
2 for 5 min at intervals of 1 h
(mitoxantrone), 2 h (SDF-1α), or 24 h (pDNA). Release was measured color-
imetrically (mitoxantrone; 650 nm), by ELISA (SDF-1α), or by PicoGreen
assay (pDNA).
In Vivo Hydrogel Release Study. For in vivo studies, an injectable formulation
of alginate was used, as described in the text. Briefly, low Mr MVG was
prepared by irradiating medical grade MVG at 5 Mrad with a cobalt source
(23). A binary formulation of 20 mg/mL low Mr MVG with 0.5 mg/mL un-
modified MVG was mixed with mitoxantrone (850 μg/mL of gel), then cross-
linked with 4% wt/vol CaSO4 (1.22 M). In vitro studies were performed to
ensure that these gels exhibited on-demand release in response to ultrasound
Fig. 4. Ultrasound-mediated local drug delivery diminishes xenograft tu-
mor growth. (A–C) Short-term studies of xenograft tumor growth and ap-
optosis when treated with ultrasound-triggered mitoxantrone. (A and B)
Representative images (A) and quantitative analysis (B) of TUNEL-stained
tumor sections from mice bearing tumors that were treated via systemic tail
vein mitoxantrone bolus or with various local delivery regimes. (C) Nor-
malized area of tumors treated via systemic mitoxantrone dose (single tail
vein injection of the maximum tolerated dose, 82.5 μg; black ●); local in-
jection of the maximum tolerated dose of mitoxantrone followed by daily
pulses of ultrasound (green ■); locally deployed mitoxantrone-laden alginate
gel (red ▲); daily pulse of ultrasound on a blank, locally deployed alginate
gel (black ▼); daily local mitoxantrone injections (black ○); or a locally
deployed, mitoxantrone-laden alginate gel subjected to daily pulses of ul-
trasound (blue ◆). Ultrasound was applied for 2.5 min. (D) Growth curves
for human MDA-MB-231 breast cancer xenografts in Nu/J mice. Tumors were
left untreated (black curve), exposed to a standard alginate gel loaded with
mitoxantrone but not ultrasound (red curve), or treated with a combination
of mitoxantrone-laden hydrogels and daily ultrasound (blue curve). Tumor
size differences were statistically significant in the mitoxantrone-laden gels
treated with daily ultrasound vs. the untreated control from day 7 until the
end of the study, and vs. the mitoxantrone-laden hydrogel from day 7 until
the end of the study with the exception of days 24–31 and days 59–63. (E)
Survival curves for mice left untreated between 70 and 180 d following
tumor implantation, after receiving no treatment (black curve), treatment
with a mitoxantrone-laden gel but no ultrasound (red curve), or treatment
with a combination of mitoxantrone-laden gel and daily ultrasound treat-
ment (blue curve). Kaplan–Meier analysis revealed a statistically significant
survival improvement in mice treated with either drug-laden gels or with
drug-laden gels exposed to a daily pulse of ultrasound, compared with mice
receiving no therapy. (F) Images of tumors explanted at the end of the study
from nonsurviving mice (no treatment) and surviving mice (drug alone and
drug-laden gel treated with daily ultrasound pulse). Error bars: SEM, n = 5–8
(short-term tumor growth studies and TUNEL staining; **P < 0.05 compared
with tail vein injection, Holm–Bonferroni test) or n = 10 (long-term tumor
growth studies and survival studies). Scale bar (F): 1 cm.
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gels (100 μL vol) were injected adjacent to tumors with a 23-gauge needle.
One day after hydrogel injection, a subset of these gels was exposed to
ultrasound for 2.5 min with a Sonics Vibra-Cell VCX130 sonicator (13-mm–
diameter horn, 120 mW/cm
2). The ultrasound transducer was coupled to
the underlying alginate hydrogel by applying a thick layer of Aquasonic 100
Medical Ultrasound Transmission Gel (Parker Laboratories). The extent of
drug release was analyzed in a blinded fashion by assessing the area of s.c.
tissue stained with mitoxantrone (blue) and normalizing to the area of
the hydrogel.
Xenograft Tumor Studies. All animal experiments were performed according
to established animal protocols. Tumors were created by injecting 10
6 MDA-
MB-231 cells (American Type Cell Culture) combined with Matrigel (BD
Biosciences) to a total volume of 200 μL (100 μL PBS and 100 μL Matrigel) into
the hindlimbs of 8-wk-old Nu/J mice (The Jackson Laboratory). Following
3 wk of tumor inoculation, the mice used for the study were normalized for
tumor size by selecting mice with tumors of area between 20 and 45 mm
2;
estimated cross-sectional areas were calculated as the area of a circle with
the average of the shortest and longest tumor dimensions. These mice were
distributed randomly in seven groups and treated as described in Table S1.
Injectable alginate formulations, as described above for in vivo release
studies, were used and injected with a 23-gauge needle into adjacent tumors.
A drug dosage of 85 μg per animal was chosen because it yields a systemic
dose of ∼3.1 mg/kg, within the dosage range previously shown to reduce
xenograft tumor burden in nude mice treated i.v. with mitoxantrone (22,
32). Ultrasound treatments were applied for 2.5 min/d with a Sonics Vibra-
Cell VCX130 sonicator (2.5 min/d, 13-mm–diameter horn, 120 mW/cm
2) once
every 24 h. As in the initial in vivo release studies, the ultrasound transducer
was coupled to the injected hydrogel by using a thick layer of Aquasonic 100
Medical Ultrasound Transmission Gel applied to the skin of the mice. Mice
were killed on day 8 (24 h after final ultrasound treatment/injection). Tissue
was formalin fixed and paraffin embedded. Next, tissue samples were
encoded so they could be sectioned and analyzed in a blinded manner.
Histological sections (5 μm) were taken through the middle of the tumor,
and TUNEL staining was performed by using a cell death kit (Roche) at the
Histology Core at the Gladstone Institute (San Francisco). For analysis of
TUNEL staining, low-resolution images of the entire tumor section were
taken of the TUNEL stain and DAPI counterstain using the 2.5× objective on
a Biorevo BZ-9000 imaging station (Keyence). The percentage of tumor la-
beling positive with DAPI then was analyzed (MATLAB; MathWorks).
For the longer study, tumors were generated as above. Thirty mice with
tumors ranging between 20 and 45 mm
2 in estimated area were assigned
randomly to three groups: no treatment, mitoxantrone-laden gel only, or
mitoxantrone-laden gel with daily ultrasound. The gel, drug, and ultrasound
conditions also were identical to those above. For both the mitoxantrone-
plus-ultrasound and mitoxantrone-only conditions, a new drug-laden gel
was injected adjacent the tumor every 2 wk. Beginning 70 d after treatment
initiation, all therapeutic treatments were stopped to assess mouse survival.
Throughout the study, tumor area was measured twice per week with dig-
ital calipers, and animals were euthanized for humane reasons in con-
sultation with the Harvard Institutional Animal Care and Use Committee,
based on the following criteria: tumor >20 mm in one direction, tumor >17
mm in two dimensions, tumor >17 mm in one dimension and mouse looking
cachectic, and tumor ulcerated through skin and nonhealing open wound
present. Mice that died of unrelated causes were not included in the
survival analysis.
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